臨床研究等提出・公開システム

Date of registration	June. 12, 2026
Last modified on	Aug. 27, 2026
Trial ID	jRCT1030260218

Scientific Title	Survey on the Burden of surgery and Patient Preferences in treatment for Rectal Cancer
Public Title	Survey on the Burden of surgery and Patient Preferences in treatment for Rectal Cancer

Contact for Scientific Queries	Name	Kanda Kingo
	Affiliation	GlaxoSmithKline K.K.
	Address	Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo, Japan
	Telephone	+81-120-561-007
	E-mail	jp.gskjrct@gsk.com
Contact for Public Queries	Name	Kanda Kingo
	Affiliation	GlaxoSmithKline K.K.
	Address	Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo, Japan
	Telephone	+81-120-561-007
	E-mail	jp.gskjrct@gsk.com

Recruitment status	Suspended

Anticipated date of first enrollment		June. 24, 2026
Actual date of first enrollment		June. 24, 2026
Target sample size		200
Study Type		Observational
Study Design	allocation	single arm study
	masking	open(masking not used)
	control	uncontrolled control
	assignment	factorial assignment
	purpose	other
Key inclusion & exclusion criteria	Inclusion Criteria	[Patients] Patients diagnosed with rectal cancer who have undergone surgery for rectal cancer. Patients aged 18 years or older at the time of consent and residing in Japan. Patients who have agreed to participate in the study. Patients who possess devices and an environment that allow access to the internet in Japanese to respond to the study questionnaire. [Physicians] Physicians with experience in treating rectal cancer at medical institutions in Japan (including surgical treatment, chemotherapy, radiotherapy, or perioperative management). Physicians who understand the purpose and methodology of the study and have agreed to participate.
	Exclusion Criteria	[Patients] Patients who are themselves employed by GlaxoSmithKline K.K. or 3H Medisolution Co., Ltd., or have family members who are employed by these companies. [Physicians] None.
	Age Minimum	18age old over
	Age Maximum	No limit
	Gender	Both
Health Condition(s) or Problem(s) Studied		Rectal cancer
Intervention(s)		NA
Primary Outcome(s)		Assesment of surgical burden and treatment satisfaction Quantification of preferences in treatment for rectal cancer
Secondary Outcome(s)		Discrepancies between patient and physician perceptions Exploration of factors influencing preferences in treatment for rectal cancer

Primary Sponsor	GlaxoSmithKline K.K.

Source of Monetary Support / Secondary Sponsor	GlaxoSmithKline K.K.

Name of Certified Review Board	Yamauchi Clinic Institutional Review Board
Address	1 Chome 15-19, Meguro-Ku, , Tokyo
Telephone	+81-3-3723-7717
E-Mail	c-irb_ug@neues.co.jp
Approval Status	Not approval
Date of approval	June. 19, 2026

Plan to share IPD	No

Countries of Recruitment（Except Japan）	none

History of Changes

No	Publication date
3	Aug. 27, 2026	(this page)	Changes
2	June. 30, 2026	Detail	Changes
1	June. 12, 2026	Detail

List of change history